JP2019501973A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501973A5
JP2019501973A5 JP2018555314A JP2018555314A JP2019501973A5 JP 2019501973 A5 JP2019501973 A5 JP 2019501973A5 JP 2018555314 A JP2018555314 A JP 2018555314A JP 2018555314 A JP2018555314 A JP 2018555314A JP 2019501973 A5 JP2019501973 A5 JP 2019501973A5
Authority
JP
Japan
Prior art keywords
composition
antibody
cancer
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018555314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501973A (ja
JP7161938B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/000511 external-priority patent/WO2017122098A2/en
Publication of JP2019501973A publication Critical patent/JP2019501973A/ja
Publication of JP2019501973A5 publication Critical patent/JP2019501973A5/ja
Application granted granted Critical
Publication of JP7161938B2 publication Critical patent/JP7161938B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018555314A 2016-01-10 2017-01-10 スーパー抗原媒介性癌免疫療法の能力を増強するための方法および組成物 Active JP7161938B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276955P 2016-01-10 2016-01-10
US62/276,955 2016-01-10
PCT/IB2017/000511 WO2017122098A2 (en) 2016-01-10 2017-01-10 Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy.

Publications (3)

Publication Number Publication Date
JP2019501973A JP2019501973A (ja) 2019-01-24
JP2019501973A5 true JP2019501973A5 (enExample) 2020-02-20
JP7161938B2 JP7161938B2 (ja) 2022-10-27

Family

ID=58737690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018555314A Active JP7161938B2 (ja) 2016-01-10 2017-01-10 スーパー抗原媒介性癌免疫療法の能力を増強するための方法および組成物

Country Status (13)

Country Link
US (4) US10314910B2 (enExample)
EP (1) EP3411409B1 (enExample)
JP (1) JP7161938B2 (enExample)
KR (2) KR20180100412A (enExample)
CN (2) CN117679499A (enExample)
AU (1) AU2017206656B2 (enExample)
CA (1) CA3010678A1 (enExample)
EA (1) EA201891601A1 (enExample)
ES (1) ES3052659T3 (enExample)
IL (1) IL260423B2 (enExample)
MX (1) MX2018008383A (enExample)
WO (1) WO2017122098A2 (enExample)
ZA (1) ZA201804565B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201891601A1 (ru) * 2016-01-10 2019-03-29 Неоткс Терапьютикс Лтд. Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей
CN112423778A (zh) * 2018-05-16 2021-02-26 杜克大学 利用免疫毒素和检查点抑制剂组合的新辅助癌症治疗
CN108840923B (zh) * 2018-06-22 2021-08-03 上海交通大学医学院附属仁济医院 一种靶向pd-l1的多肽及其应用
EA202193121A1 (ru) * 2019-05-15 2022-02-21 Неоткс Терапьютикс Лтд. Лечение рака
EP4051321A4 (en) 2019-10-30 2023-11-22 Duke University IMMUNOTHERAPY WITH COMBINATION THERAPY INCLUDING AN IMMUNOTOXIN
AU2021357520A1 (en) * 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
US20230285588A1 (en) * 2020-07-20 2023-09-14 Neotx Therapeutics Ltd. Superantigen conjugate for use in methods and compositions for treating cancer
JP7570653B2 (ja) * 2020-08-19 2024-10-22 ▲蘇▼州易慕峰生物科技有限公司 ヒト化抗体、キメラ抗原受容体、核酸、ベクター、細胞及び応用
IL307842A (en) * 2021-04-22 2023-12-01 Neotx Therapeutics Ltd Methods and compositions for treating glioblastoma
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
CN116284448B (zh) * 2023-02-14 2024-06-21 浙江大学 一种超抗原参与的三功能t细胞衔接器及其应用

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE68923027D1 (de) 1988-03-04 1995-07-20 Cancer Res Campaign Tech Antigene.
US5057604A (en) 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5284760A (en) 1989-04-03 1994-02-08 Feinstone Stephen M Techniques for producing site-directed mutagenesis of cloned DNA
US6042837A (en) 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US6126945A (en) 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US6197299B1 (en) 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
US5858363A (en) 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
JP3398957B2 (ja) 1991-12-24 2003-04-21 ザ・プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ Ｄｎａの特定部位の突然変異誘発
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US5389514A (en) 1992-08-28 1995-02-14 Fox Chase Cancer Center Method for specifically altering the nucleotide sequence of RNA
US5545716A (en) 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5519114A (en) 1993-10-29 1996-05-21 University Of Florida Research Foundation, Inc. Retroviral superantigens, superantigen peptides, and methods of use
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1538208A3 (en) 1995-06-07 2007-05-23 Regents Of The University Of Minnesota Mutants of streptococcal toxin A and methods of use
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
JPH09208491A (ja) * 1996-01-31 1997-08-12 Asahi Optical Co Ltd 免疫賦活剤
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
US6447777B1 (en) 1996-03-29 2002-09-10 David S. Terman Polymerized staphylococcal protein a for treatment of diseases
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
CN1148449C (zh) 1996-12-06 2004-05-05 明尼苏达大学董事会 链球菌毒素c突变体及其使用方法
CN1211487C (zh) 1996-12-06 2005-07-20 明尼苏达大学董事会 链球菌毒素a突变体及其使用方法
US6774218B2 (en) 1996-12-06 2004-08-10 Regents Of The University Of Minnesota Mutants of streptococcal toxin C and methods of use
US6340461B1 (en) 1996-12-17 2002-01-22 David Stephen Terman Superantigen based methods and compositions for treatment of diseases
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US7087235B2 (en) 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
BR9815493A (pt) 1997-07-21 2000-10-31 Pharmacia & Upjohn Ab Citólise dirigida de células-alvo, agentes e composições que causam citólise, e compostos que podem ser usados para produzir os agentes
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
WO1999036433A2 (en) 1998-01-14 1999-07-22 Morphogenesis, Inc. Materials and methods for treating oncological disease
BR9910253A (pt) 1998-05-19 2002-09-17 Avidex Ltd Receptor de célula t solúvel
DE69940157D1 (en) 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20020177551A1 (en) 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20030157113A1 (en) 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
US20010046501A1 (en) 2000-03-14 2001-11-29 Johnson Howard M. Superantigen enhancement of specific immune responses
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
JP4283430B2 (ja) 2000-09-26 2009-06-24 株式会社カネカ エンテロトキシンの吸着材、吸着除去方法および吸着器
WO2002045739A1 (en) 2000-12-04 2002-06-13 Auckland Uniservices Limited Immunomodulatory constructs and their uses
CN1369550A (zh) 2001-02-16 2002-09-18 沈阳协合集团有限公司 一种金黄色葡萄球菌的培养物及其制备方法
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
MXPA04001974A (es) 2001-08-31 2004-07-16 Avidex Ltd Receptor de celula t soluble.
AU2003235593A1 (en) 2002-01-10 2003-07-30 National Jewish Medical And Research Center USE OF SOLUBLE GammaDelta T CELL RECEPTORS FOR REGULATING T CELL FUNCTION
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
US6926694B2 (en) 2003-05-09 2005-08-09 Medsolve Technologies, Llc Apparatus and method for delivery of therapeutic and/or diagnostic agents
US7198398B2 (en) 2004-06-30 2007-04-03 Fiberstars, Inc. Adjustable-aim light pipe fixture
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US11180572B2 (en) * 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
CN103566377A (zh) * 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
US20150301058A1 (en) * 2012-11-26 2015-10-22 Caris Science, Inc. Biomarker compositions and methods
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
FI4141032T3 (fi) 2014-11-20 2024-07-31 Hoffmann La Roche T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
EA201891601A1 (ru) * 2016-01-10 2019-03-29 Неоткс Терапьютикс Лтд. Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей

Similar Documents

Publication Publication Date Title
JP2023528036A5 (enExample)
Aranda et al. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy
JP2018501197A5 (enExample)
JP2025172086A5 (enExample)
HRP20211346T1 (hr) Kombinirani pripravci za liječenje raka
JP2018508483A5 (enExample)
Duarte et al. Gastric cancer: basic aspects
RU2013141976A (ru) Новые модуляторы и способы их применения
MX2009010120A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos.
WO2016191643A4 (en) Tigit-binding agents and uses thereof
IL265541B2 (en) Bispecific antibodies and compounds containing them for the treatment of cancer
JP2018523686A5 (enExample)
JP7370376B2 (ja) Ｍｉｃａ／ｂシェディングをブロックする抗ｍｉｃａ／ｂ抗体および使用方法
JP2017506217A5 (enExample)
JP2018531914A5 (enExample)
IL253462B (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
JP2016539083A5 (enExample)
JP2018515474A5 (enExample)
WO2014012007A4 (en) Rspo3 binding agents and uses thereof
IL278423B2 (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer
JP2021512151A5 (enExample)
JP2022500410A5 (enExample)
US10752688B2 (en) Anti-human TIM-3 antibodies and methods of use thereof
JP2020522512A5 (enExample)
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей